Vadastuximab talirine - Seattle Genetics

Drug Profile

Vadastuximab talirine - Seattle Genetics

Alternative Names: 33 A; Anti-CD33A targeted ADC - Seattle Genetics; SGN CD33A

Latest Information Update: 22 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies; Pyrroles
  • Mechanism of Action Cytoadhesin receptor antagonists; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase I/II Myelodysplastic syndromes

Most Recent Events

  • 10 Apr 2018 Seattle Genetics completes a phase I trial in Acute myeloid leukaemia in USA (NCT02326584)
  • 08 Dec 2017 Seattle Genetics completes a phase I trial in Acute myeloid leukaemia (Monotherapy, Combination therapy) in USA (NCT01902329)
  • 22 Jun 2017 Efficacy and adverse events data from a phase I trial in Acute myeloid leukaemia presented at the Congress of the European Hematology Association (EHA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top